Meridian Bioscience (NASDAQ:VIVO) Downgraded by Zacks Investment Research to Hold

Meridian Bioscience} stock has undergone multiple analysts rating changes in the recent past.  Meridian Bioscience Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More Meridian Bioscience (NASDAQ:VIVO) Downgraded by Zacks Investment Research to Hold

How Have the Numbers Shaped Up for Meridian Bioscience (NASDAQ:VIVO)

Earnings results for Meridian Bioscience , Analyst Opinion on Meridian Bioscience , Earnings and Valuation of (NASDAQ:VIVO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More How Have the Numbers Shaped Up for Meridian Bioscience (NASDAQ:VIVO)

Analyst Valuation and EPS Growth for Meridian Bioscience (NASDAQ:VIVO)

Earnings results for Meridian Bioscience , Analyst Opinion on Meridian Bioscience , Earnings and Valuation of (NASDAQ:VIVO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Analyst Valuation and EPS Growth for Meridian Bioscience (NASDAQ:VIVO)

Factors Likely to Have Influenced Earnings Results Meridian Bioscience (NASDAQ:VIVO)

Earnings results for Meridian Bioscience , Analyst Opinion on Meridian Bioscience , Earnings and Valuation of (NASDAQ:VIVO), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Factors Likely to Have Influenced Earnings Results Meridian Bioscience (NASDAQ:VIVO)